Müssigbrodt A, Hindricks G, Sommer P
Herzzentrum, Abteilung für Elektrophysiologie, Universität Leipzig, Strümpellstrasse 39, Leipzig, Germany.
Herzschrittmacherther Elektrophysiol. 2013 Mar;24(1):2-6. doi: 10.1007/s00399-013-0247-9. Epub 2013 Mar 14.
Atrial fibrillation (AF) is the arrhythmia that causes most arrhythmia-associated hospitalisations in the western world. In Germany it affects approximately 3 million people. The limited success rates of drug treatment stimulated an exploration of interventional treatment options for AF. As our knowledge on initiating triggers and perpetuating substrate of AF expanded, catheter ablation techniques have been developed. In this article we review the patient selection criteria according to the current guidelines, and discuss established and recently found risk factors for recurrences of AF and complications by catheter ablation that may influence current patient selection for catheter ablation of AF.
心房颤动（AF）是导致西方世界大多数心律失常相关住院治疗的心律失常。在德国，它影响着大约300万人。药物治疗成功率有限，促使人们探索房颤的介入治疗方案。随着我们对房颤起始触发因素和持续基质的认识不断扩展，导管消融技术得以发展。在本文中，我们根据当前指南回顾患者选择标准，并讨论已确定的和最近发现的房颤复发风险因素以及导管消融并发症，这些可能会影响当前房颤导管消融的患者选择。
